Oncology Business Review (OBR) is a primary information resource dedicated exclusively to the business of oncology. About Us»
(Bloomberg Businessweek) September 2, 2010 - People with osteoporosis who take drugs such as Boniva (ibandronate), Fosamax (alendronate) or Actonel (risedronate) to strengthen their bones may be at an increased risk of esophageal cancer, British researchers report.
read article »
(Reuters) September 3, 2010 - Celldex Therapeutics Inc said its partner Pfizer ended the deal to co-develop Celldex's cancer vaccine, its lead product, as the program was no longer a strategic priority for the drug giant.
read article »
![]() |
Our free daily oncology focused e-news service. Subscribe» | Search Archives» | |
Oncology Business Review is our industry trade journal with carefully developed, exclusive oncology industry content. SUBSCRIBE Today!
Our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register for OBR green today. View OBR green.